Historically, the median overall survival of metastatic melanoma patients was less than 1 year and long-term survivors were rare. Recent advances in therapies have dramatically shifted this landscape...
Areas covered: This is a comprehensive review of the literature on the role of pembrolizumab in melanoma.
The FDA has expanded the approved use of Yervoy (ipilimumab), from BMS, to include a new use as adjuvant therapy...
The purpose of this study is to show that Nivolumab and/or Nivolumab in combination with Ipilimumab will extend progression free...
BMS has announced positive results from a Phase II trial (CheckMate -069), evaluating the Opdivo (nivolumab)+Yervoy (ipilimumab) regimen versus Yervoy...
Areas covered: Encorafenib in combination with bimetinib offers a new approach that may offer benefits over existing BRAF/MEK inhibitor combinations.
Immunocore has announced trial results showing that overall survival (OS) was statistically significantly improved with IMCgp100 (tebentafusp) compared with investigator’s choice of therapy as treatment of patients with metastatic uveal melanoma in the phase III IMCgp100-202 study (NCT03070392).
BMS has announced that the FDA has accepted for filing and review the supplemental Biologics License Application (sBLA) for Yervoy...
Bristol-Myers Squibb announced that the European Commission (EC) has approved Opdivo + Yervoy (nivolumab + ipilimumab) for the treatment of...